JP4896827B2 - 角層のＡＧＥｓの鑑別方法 - Google Patents
角層のＡＧＥｓの鑑別方法 Download PDFInfo
- Publication number
- JP4896827B2 JP4896827B2 JP2007168356A JP2007168356A JP4896827B2 JP 4896827 B2 JP4896827 B2 JP 4896827B2 JP 2007168356 A JP2007168356 A JP 2007168356A JP 2007168356 A JP2007168356 A JP 2007168356A JP 4896827 B2 JP4896827 B2 JP 4896827B2
- Authority
- JP
- Japan
- Prior art keywords
- ages
- stratum corneum
- mass
- image
- stained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000434 stratum corneum Anatomy 0.000 title claims description 54
- 238000000034 method Methods 0.000 claims description 23
- 238000011532 immunohistochemical staining Methods 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 5
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 238000012850 discrimination method Methods 0.000 claims 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 61
- 239000002537 cosmetic Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 210000000245 forearm Anatomy 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 229940049657 cyclomethicone 5 Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000037070 skin defense Effects 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007168356A JP4896827B2 (ja) | 2007-06-27 | 2007-06-27 | 角層のＡＧＥｓの鑑別方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007168356A JP4896827B2 (ja) | 2007-06-27 | 2007-06-27 | 角層のＡＧＥｓの鑑別方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009008460A JP2009008460A (ja) | 2009-01-15 |
| JP2009008460A5 JP2009008460A5 (https=) | 2010-07-08 |
| JP4896827B2 true JP4896827B2 (ja) | 2012-03-14 |
Family
ID=40323694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007168356A Active JP4896827B2 (ja) | 2007-06-27 | 2007-06-27 | 角層のＡＧＥｓの鑑別方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4896827B2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5275898B2 (ja) * | 2009-05-21 | 2013-08-28 | ポーラ化成工業株式会社 | 皮膚状態の評価方法 |
| JP5394501B2 (ja) | 2009-10-02 | 2014-01-22 | シャープ株式会社 | 血管状態モニタリング方法 |
| JP5386634B2 (ja) * | 2010-03-19 | 2014-01-15 | シャープ株式会社 | 測定結果処理装置、測定システム、測定結果処理方法、制御プログラムおよび記録媒体 |
| CN117222876A (zh) | 2021-04-14 | 2023-12-12 | 美国西门子医学诊断股份有限公司 | 具有多个照明源的诊断仪器及其方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001122758A (ja) * | 1999-10-22 | 2001-05-08 | Pola Chem Ind Inc | ＡＧＥｓ分解作用を有する老化肌防御、改善化粧料 |
| JP2003261432A (ja) * | 2002-03-07 | 2003-09-16 | Noevir Co Ltd | 皮膚外用剤 |
| JP2003300961A (ja) * | 2002-04-11 | 2003-10-21 | Kumamoto Technology & Industry Foundation | 新規ピリジニウム誘導体およびその利用方法 |
| JP2004340935A (ja) * | 2003-04-21 | 2004-12-02 | Shiseido Co Ltd | 角層における酸化タンパク質の評価方法 |
| JP2007119373A (ja) * | 2005-10-26 | 2007-05-17 | Arkray Inc | メイラード反応生成物分解剤およびそれを用いた飲食品 |
-
2007
- 2007-06-27 JP JP2007168356A patent/JP4896827B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009008460A (ja) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klotz et al. | The health effects of aluminum exposure | |
| Yaegaki et al. | Standardization of clinical protocols in oral malodor research | |
| Heiss et al. | Cerebral glucose metabolism as a predictor of rehabilitation after ischemic stroke. | |
| JP6943960B2 (ja) | 乾燥の徴候を呈している皮膚を診断するための方法 | |
| JP6022260B2 (ja) | 皮膚状態の評価方法 | |
| JP4896827B2 (ja) | 角層のＡＧＥｓの鑑別方法 | |
| Gui et al. | Fasting plasma glucose correlates with angiographic coronary artery disease prevalence and severity in Chinese patients without known diabetes | |
| CN105699654A (zh) | 皮肤角质层的ngal的表达量的用途 | |
| JP2012098097A (ja) | 蛍光ｘ線分析による生体内金属元素検査方法 | |
| Naveed et al. | Intelligent diabetes detection system based on tongue datasets | |
| Lai et al. | Assessment of mitochondrial respiratory capacity using minimally invasive and noninvasive techniques in persons with spinal cord injury | |
| JP2009247430A (ja) | 皮膚ａｇｅの非侵襲的鑑別法 | |
| JP5665583B2 (ja) | 肌状態評価方法 | |
| Veras et al. | Identification of biomarkers in diabetic nails by Raman spectroscopy | |
| Earthman et al. | Dudrick Research Symposium 2015—lean tissue and protein in health and disease: key targets and assessment strategies | |
| CN118141328A (zh) | 一种适用于分化型甲状腺癌患者的术后自助评估系统 | |
| JP5711951B2 (ja) | アディポネクチン及び／又はインスリンの測定方法 | |
| TWI541506B (zh) | 皮膚壓力蓄積的評價方法 | |
| JP7792788B2 (ja) | 皮膚角層中のフェニルアラニンを指標とする肌の総合力の評価方法 | |
| JP6397733B2 (ja) | ニキビ肌評価方法 | |
| Chien et al. | Clinical implications in the incidence and associated risk factors of gallstone disease among elderly type 2 diabetics in Kinmen, Taiwan | |
| JP2021117164A (ja) | 皮膚炎症状態の評価方法 | |
| Majumder et al. | PS-BPP06-5: PREVALENCE AND DETERMINANTS OF HYPERTENSION AMONG ADULTS: A CROSS SECTIONAL SURVEY OF ONE TRIBAL AREA IN BANGLADESH | |
| JP7256069B2 (ja) | 生体の酸化ストレスの評価方法 | |
| KR20190042392A (ko) | 타액을 이용한 유방암 감지 키트 및 이를 이용한 유방암 감지 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100524 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100524 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110614 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110615 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110811 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111213 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4896827 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20180106 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |